Atossa Therapeutics (ATOS) Expected to Announce Quarterly Earnings on Tuesday

Atossa Therapeutics (NASDAQ:ATOS) will likely be posting its quarterly earnings results on Tuesday, March 25th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics Trading Up 5.4 %

NASDAQ:ATOS opened at $0.75 on Friday. Atossa Therapeutics has a 1-year low of $0.66 and a 1-year high of $2.31. The firm has a fifty day simple moving average of $0.81 and a 200 day simple moving average of $1.12. The stock has a market capitalization of $94.83 million, a PE ratio of -3.43 and a beta of 1.20.

Institutional Investors Weigh In On Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE lifted its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the quarter. Bank of America Corp DE owned about 0.09% of Atossa Therapeutics worth $105,000 as of its most recent SEC filing. Institutional investors and hedge funds own 12.74% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Ascendiant Capital Markets raised their price target on Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a report on Wednesday, March 12th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.